人血白蛋白治疗进展性脑梗死的疗效及其影响因素分析
Clinical efficacy of human albumin in the treatment of progressive cerebral infarction, and its affecting factors
-
摘要: 目的:探讨人血白蛋白治疗进展性脑梗死的疗效及其影响因素。方法:纳入130例进展性脑梗死患者,分别给予人血白蛋白+对症支持治疗(观察组)67例和仅对症支持治疗(对照组)63例,治疗10 d后比较2组患者的血黏度、国立卫生研究院卒中量表(美国)评分(NIHSS)、疗效和不良反应,采用logistic回归分析疗效的影响因素。结果:2组患者治疗后的高、中和低切黏度均较治疗前显著降低(P<0.01),观察组治疗后的高、中和低切黏度降低程度均显著高于对照组(P<0.01);2组患者治疗后NIHSS均较治疗前显著降低(P<0.01),且观察组NIHSS评分降低程度显著高于对照组(P<0.01);观察组和对照组的总有效率分别为89.55%和69.84%,观察组患者治疗效果明显高于对照组(P<0.01);观察组和对照组的不良反应发生率为7.46%和1.59%,差异无统计学意义(P>0.05);治疗前高切黏度对疗效有显著影响(P<0.05,OR=0.643,OR 95% CI:0.442~1.241)。结论:人血白蛋白治疗进展性脑梗死安全有效,但受血黏度影响,值得临床推广应用。Abstract: Objective: To explore the clinical efficacy of human albumin in the treatment of progressive cerebral infarction,and its affecting factors.Methods: Among 130 patients with progressive cerebral infarction,67 cases were treated with human serum albumin combined with symptomatic treatment(observation group),and 63 cases were treated with symptomatic treatment(control group).The blood viscosity,National Institutes of Health Stroke Scale(NIHSS) score,efficacy and adverse reaction between two groups were compared after 10 days of treatment.The affecting factors of curative efficacy were analyzed using the logistics regression.Results: Compared before treatment,the high,middle and low shear viscosity in two groups were significantly decreased after treatment(P<0.01),and the decreasing degree of which in observation group was significantly higher than that in control group(P<0.01).Compared before treatment,the NIHSS scores in two groups were significantly decreased after treatment(P<0.01),and the decreasing degree of NIHSS score in observation group was significantly higher than that in control group(P<0.01).The total efficiency rates in observation group and control group were 89.55% and 69.84%,respectively,and the treatment effect in observation group was significantly higher than that in control group(P<0.01).The incidences of adverse reaction in observation and control group were 7.46% and 1.59%,respectively,the difference of which was not statistically significant(P>0.05).Before treatment,the high shear viscosity effected significantly on the efficacy(P<0.05,OR=0.643,OR 95%CI:0.442-1.241).Conclusions: Human serum albumin in treating the progressive cerebral infarction is safe and effective,but which is affected by the blood viscosity,and worthy of clinic application.
-
Key words:
- cerebral infarction /
- human albumin /
- efficacy /
- factor
-
[1] CHENY,LIU Y,LUO C,et al.Analysis of multiple factors involved in acute progressive cerebral infarction and extraand intracranial arterial lesions[J].Exp Ther Med,2014,7(6):1495. [2] GAO X.A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction[J].Exp Ther Med,2013,5(4):1244. [3] 杨秀平,袁建新,何洪涛,等.进展性脑梗死的影响因素[J].中国老年学杂志,2013,33(6):1387. [4] WILKES MM,NAVICKISR J.Patient survival after human albumin administration:a meta-analysis of randomized,controlled trials[J].Ann Intern Med,2001,135(3):149. [5] 周虹,王华光,刘丽宏.468例人血白蛋白临床应用调查与分析[J].中国药物应用与监测,2014,11(5):311. [6] 夏磊,程谦涛,王丽君,等.人血白蛋白对脑出血继发损伤的影响及机制[J].广东医学,2013,33(24):3806. [7] 吴逊.全国第四届脑血管病学术会议纪要[J].卒中与神经疾病,1997,4(2):105. [8] 陶子荣.我国脑卒中患者临床神经功能缺损评分标准信度,效度及敏感度的评价[J].第二军医大学学报,2009,30(3):283. [9] 雷东华.小剂量尿激酶联合低分子肝素治疗急性进展性脑梗死疗效分析[J].中国实用神经疾病杂志,2013,16(7):40. [10] YAMASAKI K,CHUANG VTG,MARUYAMA T,et al.Albumin-drug interaction and its clinical implication[J].Biochimica Et Biophysica Acta,2013,1830(12):5435. [11] 赵大辉,王桂茹,陈秀文,等.人血白蛋白的生理功能及其应用护理研究[J].护理研究(中旬版),2011(2):380. [12] 殷世忠,宋和平,徐德强.人血白蛋白临床应用进展[J].齐鲁药事,2012,31(8):476. [13] 冯文清,张孝良,吴保鑫.小剂量尿激酶,低分子肝素联合人血白蛋白治疗进展性脑梗死40例疗效观察[J].中国实用神经疾病杂志,2011,14(5):43. [14] 许虹娟.小剂量尿激酶、低分子肝素及人血白蛋白联合在进展性脑梗死治疗中的临床应用研究[J].中国卫生产业,2013,10(31):149. [15] 黄睿智,刘皋林,祝德秋,等.我院人血白蛋白临床应用现状及用于脑梗死患者的临床疗效评价[J].中国药房,2015,26(14):1899.
计量
- 文章访问数: 3876
- HTML全文浏览量: 457
- PDF下载量: 121
- 被引次数: 0